U.S. delays mRNA technology, jeopardizing Avian Influenza control

The United States' recent decision to cancel a $590 million contract with Moderna for the development of an mRNA-based avian influenza vaccine has sparked concern among public health experts.

David Corredor

The United States’ recent decision to cancel a $590 million contract with Moderna for the development of an mRNA-based avian influenza vaccine has sparked concern among public health experts. The move, attributed to a strategic shift in federal vaccine policy under the new administration, comes at a time when outbreaks of H5N1 avian flu continue to affect poultry, dairy cattle, and even humans across the country.

• Moderna’s vaccine candidate, mRNA-1018, had shown promising results in Phase 1/2 trials, with nearly 98% of participants developing protective antibody levels within three weeks of the second dose.
• The vaccine also demonstrated a favorable safety profile, with most adverse effects being mild to moderate.
• Despite this, the Department of Health and Human Services (HHS) terminated the contract, citing a reassessment of public health priorities and a focus on more immediate threats.

This decision has raised alarms among scientists and health policy experts who argue that mRNA technology is crucial for pandemic preparedness. Unlike traditional vaccines, which require months to produce using egg-based methods, mRNA vaccines can be designed and manufactured rapidly once a virus’s genetic sequence is known. This speed is vital in responding to fast-moving outbreaks and emerging variants.

The cancellation also reflects broader regulatory changes under HHS Secretary Robert F. Kennedy Jr., who has been critical of mRNA vaccines. These shifts have led to a reevaluation of federal funding strategies, potentially sidelining technologies that were instrumental during the COVID-19 pandemic.

• Moderna, facing declining revenues from its COVID-19 vaccine, is now exploring alternative funding sources, including private investment and international partnerships, to continue development of the avian flu vaccine.
• The company maintains that proactive vaccine development remains essential, especially given the risk of H5N1 mutating into a form capable of human-to-human transmission.

Experts warn that the delay in advancing mRNA-based solutions could leave the U.S. vulnerable in the event of a future pandemic. The decision not only undermines years of scientific progress but also sends a troubling signal to biotech innovators about the reliability of government support.